Brief: Rezolute Announces Phase 3 SunRIZE Study Results In Congenital Hyperinsulinism
11/12/2025 12:48
Dec 11 (Reuters) - Rezolute Inc RZLT.O: REZOLUTE INC: ANNOUNCES PHASE 3 SUNRIZE STUDY RESULTS IN CONGENITAL HYPERINSULINISM REZOLUTE INC - PHASE 3 STUDY FAILS TO MEET PRIMARY ENDPOINT REZOLUTE INC - SERIOUS HYPERSENSITIVITY REACTIONS IN TWO STUDY PARTICIPANTS REZOLUTE INC: PHASE 3 UPLIFT STUDY FOR TUMOR HI IS ONGOING WITH TOPLINE RESULTS EXPECTED IN SECOND HALF OF 2026 Source text: ID:nGNX9gKD0D Further company coverage: RZLT.O ((Reuters.Briefs@thomsonreuters.com;))